<DOC>
	<DOCNO>NCT00532155</DOCNO>
	<brief_summary>The primary objective study demonstrate overall survival improvement aflibercept + docetaxel compare docetaxel + placebo second line treatment participant locally advance metastatic non-small cell lung cancer ( NSCLC ) . The secondary objective compare efficacy parameter , assess overall safety two treatment arm , assess pharmacokinetics intravenous ( IV ) aflibercept participant population determine immunogenicity IV aflibercept participant .</brief_summary>
	<brief_title>A Study Aflibercept Versus Placebo Patients With Second-Line Docetaxel Locally Advanced Metastatic Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description>The study include : - A screening visit 21 day prior randomization - Randomization baseline ( Treatment initiate 3 day randomization ) - A treatment period 3-week treatment cycle participant meet follow discontinuation criterion : progressive disease , unacceptable toxicity , refuse study treatment - A post study treatment follow-up period ( visit schedule every 8 week death end study )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histological/cytological proven locally advance metastatic nonsmall cell lung cancer Disease progression one , one , prior anticancer therapy platinumbased advanced metastatic disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 Adequate renal , liver bone marrow function Squamous histology/cytology Less 28 day elapse prior treatment radiotherapy , surgery , chemotherapy time randomization Prior isotope therapy , whole pelvic radiotherapy , radiotherapy &gt; 25 % bone marrow Prior docetaxel treatment Uncontrolled hypertension The information intend contain consideration relevant participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>angiogenesis inhibitor</keyword>
	<keyword>chemotherapy</keyword>
</DOC>